Many studies with conflicting and ambiguous outcomes have been published investigating the pharmacogenomics of etanercept, infliximab and adalimumab in RA populations, and to date there have been no predictive anti-TNF genomic biomarkers established for clinical use. Here, TNF is linked to rheumatoid arthritis.